GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SeaStar Medical Holding Corp (NAS:ICU) » Definitions » ROE %

SeaStar Medical Holding (SeaStar Medical Holding) ROE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is SeaStar Medical Holding ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. SeaStar Medical Holding's annualized net income for the quarter that ended in Mar. 2024 was $-50.79 Mil. SeaStar Medical Holding's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $-9.17 Mil. Therefore, SeaStar Medical Holding's annualized ROE % for the quarter that ended in Mar. 2024 was N/A%.

The historical rank and industry rank for SeaStar Medical Holding's ROE % or its related term are showing as below:

ICU's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -43.31
* Ranked among companies with meaningful ROE % only.

SeaStar Medical Holding ROE % Historical Data

The historical data trend for SeaStar Medical Holding's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SeaStar Medical Holding ROE % Chart

SeaStar Medical Holding Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE %
- - - -

SeaStar Medical Holding Quarterly Data
Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SeaStar Medical Holding's ROE %

For the Biotechnology subindustry, SeaStar Medical Holding's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SeaStar Medical Holding's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's ROE % distribution charts can be found below:

* The bar in red indicates where SeaStar Medical Holding's ROE % falls into.



SeaStar Medical Holding ROE % Calculation

SeaStar Medical Holding's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-26.232/( (-20.762+-13.87)/ 2 )
=-26.232/-17.316
=N/A %

SeaStar Medical Holding's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-50.788/( (-13.87+-4.473)/ 2 )
=-50.788/-9.1715
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


SeaStar Medical Holding  (NAS:ICU) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-50.788/-9.1715
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-50.788 / 0)*(0 / 5.6265)*(5.6265 / -9.1715)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-50.788/-9.1715
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-50.788 / -50.788) * (-50.788 / -15.8) * (-15.8 / 0) * (0 / 5.6265) * (5.6265 / -9.1715)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 3.2144 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


SeaStar Medical Holding ROE % Related Terms

Thank you for viewing the detailed overview of SeaStar Medical Holding's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


SeaStar Medical Holding (SeaStar Medical Holding) Business Description

Traded in Other Exchanges
N/A
Address
3513 Brighton Boulevard, Suite 410, Denver, CO, USA, 80216
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
Executives
Heel Kenneth Van director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Kevin Chung officer: Chief Medical Officer C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Richard D. Russell director 3201 W BAY VISTA AVE, TAMPA FL 33611
Bruce M. Rodgers director 302 KNIGHTS RUN AVE., STE. 1000, TAMPA FL 33602
Andres Lobo director C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Caryl Baron officer: See Remarks C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Eric Schlorff director, officer: Chief Executive Officer C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Rick Barnett director C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Allan Collins director C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Dow Employees' Pension Plan Trust 10 percent owner 2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674
Union Carbide Employees' Pension Plan Trust 10 percent owner 2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674
Martin A Traber director 100 N TAMPA STREET, SUITE 2700, TAMPA FL 33602
Lm Funding America, Inc. 10 percent owner 1200 WEST PLATT STREET, SUITE 100, TAMPA FL 33606
Craig E Burson director 400 N. PARK AVENUE, UNIT 10B, BRECKENRIDGE CO 80424
Bruce H Bennett director 3929 ARLINGTON DRIVE, PALM HARBOR FL 34685

SeaStar Medical Holding (SeaStar Medical Holding) Headlines

From GuruFocus